Compare AMCX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMCX | FHTX |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.2M | 360.8M |
| IPO Year | 2011 | 2020 |
| Metric | AMCX | FHTX |
|---|---|---|
| Price | $7.70 | $5.63 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $6.50 | ★ $11.43 |
| AVG Volume (30 Days) | ★ 360.5K | 200.8K |
| Earning Date | 02-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,316,303,000.00 | $24,518,000.00 |
| Revenue This Year | N/A | $40.91 |
| Revenue Next Year | N/A | $11.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.41 | $2.95 |
| 52 Week High | $10.28 | $6.95 |
| Indicator | AMCX | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 50.19 |
| Support Level | $7.69 | $5.46 |
| Resistance Level | $8.11 | $6.29 |
| Average True Range (ATR) | 0.27 | 0.39 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 16.98 | 14.08 |
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.